接受肝细胞癌选择性内放射治疗患者在多期CT/MRI上LI-RADS放射治疗反应评估的时间演变

Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.

作者信息

Wei Hong, Jiang Hanyu, Yoo Jeongin, Kim Jae Hyun, Kang Hyo-Jin, Wu Yuanan, Liu Rongbo, Kim Hyo-Cheol, Lee Jeong Min

机构信息

Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.

Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Eur Radiol. 2025 May 17. doi: 10.1007/s00330-025-11659-1.

Abstract

OBJECTIVES

To assess the temporal evolution and interobserver agreement of the early categories per the liver imaging reporting and data system (LI-RADS) radiation treatment response assessment (TRA) algorithm in patients receiving selective internal radiation therapy (SIRT) with Yttrium-90 for hepatocellular carcinoma (HCC).

MATERIALS AND METHODS

This single-center retrospective study included consecutive patients with treatment-naïve HCC who underwent serial contrast-enhanced CT/MRI before and after SIRT. Three masked radiologists independently evaluated response at 3-6 months. Another senior radiologist assessed response at 9, 12, 15, 18, 21, 24, and > 24 months after comprehensive review of available clinical-radiological information.

RESULTS

65 patients (mean age, 66.7 ± 11.2 years; 48 men) were included. At 3-6 months after SIRT, 47.7% (31/65) of lesions were assigned to the nonprogressing category, and the remaining 52.3% (34/65) to the nonviable category. Among early nonprogressing lesions, 64.5% (20/31) regressed to the nonviable category, 25.8% (8/31) remained nonprogressing, and 9.7% (3/31) evolved into the viable category at ≥ 12 months. The nonprogressing category decreased in number over time, with 61.3% (19/31) conversion to the nonviable category at 9 months. Among the early nonviable lesions, 91.2% (31/34) remained nonviable at ≥ 12 months, and 8.8% (3/34) evolved into the viable category. Agreement for the 3-6 months LR-TR category assignment was moderate (kappa = 0.46) with CT but almost perfect (kappa = 0.85) with MRI.

CONCLUSIONS

SIRT induced a delayed and sustained response in the majority of HCC patients after ≥ 12 months. MRI demonstrated superior agreement over CT in assessing response at 3-6 months.

KEY POINTS

Question Tumor response to SIRT can change; there is limited evidence on the evolution of the imaging appearance of HCC following SIRT. Findings Sixty-four and five-tenths of early nonprogressing lesions regressed to nonviable, and 91.2% of early nonviable lesions remained free of viability. LR-TR category assignment agreement was moderate with CT but almost perfect with MRI. Clinical relevance SIRT induced a delayed and sustained response in HCC, underscoring the necessity of dynamic evaluation of long-term changes in treated lesions. MRI with subtraction imaging may be preferred over CT for long-term monitoring, which may help prevent premature retreatment decisions.

摘要

目的

评估接受钇-90选择性内放射治疗(SIRT)的肝细胞癌(HCC)患者,根据肝脏影像报告和数据系统(LI-RADS)放射治疗反应评估(TRA)算法得出的早期分类的时间演变及观察者间一致性。

材料与方法

本单中心回顾性研究纳入了初治HCC患者,这些患者在SIRT前后接受了系列对比增强CT/MRI检查。三名盲法放射科医生独立评估3至6个月时的反应。另一名资深放射科医生在全面回顾可用的临床放射学信息后,评估9、12、15、18、21、24及>24个月时的反应。

结果

纳入65例患者(平均年龄66.7±11.2岁;48例男性)。SIRT后3至6个月,47.7%(31/65)的病灶被归类为无进展类别,其余52.3%(34/65)为无活性类别。在早期无进展病灶中,6至12个月时64.5%(20/31)退化为无活性类别,25.8%(8/31)仍无进展,9.7%(3/31)演变为活性类别。无进展类别数量随时间减少,9个月时61(19/31)转变为无活性类别。在早期无活性病灶中,6至12个月时91.2%(31/34)仍无活性,8.8%(3/34)演变为活性类别。3至6个月LR-TR类别分配的一致性,CT检查为中等(kappa=0.46),MRI检查几乎为完美(kappa=0.85)。

结论

SIRT在≥12个月后在大多数HCC患者中诱导了延迟且持续的反应。MRI在评估3至6个月时的反应方面显示出比CT更好的一致性。

关键点

问题肿瘤对SIRT的反应可能会改变;关于SIRT后HCC影像学表现演变的证据有限。发现64.5%的早期无进展病灶退化为无活性,91.2%的早期无活性病灶仍无活性。LR-TR类别分配一致性,CT检查为中等,MRI检查几乎为完美。临床意义SIRT在HCC中诱导了延迟且持续的反应,强调了动态评估治疗病灶长期变化的必要性。对于长期监测,采用减影成像的MRI可能比CT更可取,这可能有助于防止过早做出再次治疗的决定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索